FDA Accepts for Review Merck's Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine
February 20, 2014 at 08:35 AM EST
Merck (NYSE: MRK ), known as MSD outside the United States and Canada, announced today that the Biologics License Application for V503, its investigational 9-valent human papillomavirus (HPV) vaccine, has been accepted for standard review by the U.S. Food and Drug Administration. About Merck Today's Merck is a global